Literature DB >> 23176581

Tumor-suppressive microRNA-135a inhibits cancer cell proliferation by targeting the c-MYC oncogene in renal cell carcinoma.

Yasutoshi Yamada1, Hideo Hidaka, Naohiko Seki, Hirofumi Yoshino, Takeshi Yamasaki, Toshihiko Itesako, Masayuki Nakagawa, Hideki Enokida.   

Abstract

Recently, many studies have suggested that microRNAs (miRNAs) are involved in cancer cell development, invasion, and metastasis of various types of human cancers. In a previous study, miRNA expression signatures from renal cell carcinoma (RCC) revealed that expression of microRNA-135a (miR-135a) was significantly reduced in cancerous tissues. The aim of this study was to investigate the functional significance of miR-135a and to identify miR-135a-mediated molecular pathways in RCC cells. Restoration of mature miR-135a significantly inhibited cancer cell proliferation and induced G0 /G1 arrest in the RCC cell lines caki2 and A498, suggesting that miR-135a functioned as a potential tumor suppressor. We then examined miR-135a-mediated molecular pathways using genome-wide gene expression analysis and in silico analysis. A total of 570 downregulated genes were identified in miR-135a transfected RCC cell lines. To investigate the biological significance of potential miR-135a-mediated pathways, we classified putative miR-135a-regulated genes according to the Kyoto Encyclopedia of Genes and Genomics pathway database. From our in silico analysis, 25 pathways, including the cell cycle, pathways in cancer, DNA replication, and focal adhesion, were significantly regulated by miR-135a in RCC cells. Moreover, based on the results of this analysis, we investigated whether miR-135a targeted the c-MYC gene in RCC. Gain-of-function and luciferase reporter assays showed that c-MYC was directly regulated by miR-135a in RCC cells. Furthermore, c-MYC expression was significantly upregulated in RCC clinical specimens. Our data suggest that elucidation of tumor-suppressive miR-135a-mediated molecular pathways could reveal potential therapeutic targets in RCC.
© 2012 Japanese Cancer Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23176581      PMCID: PMC7657112          DOI: 10.1111/cas.12072

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  48 in total

Review 1.  Myc goes global: new tricks for an old oncogene.

Authors:  Paul S Knoepfler
Journal:  Cancer Res       Date:  2007-06-01       Impact factor: 12.701

Review 2.  Transcriptional regulation and transformation by Myc proteins.

Authors:  Sovana Adhikary; Martin Eilers
Journal:  Nat Rev Mol Cell Biol       Date:  2005-08       Impact factor: 94.444

3.  MYC pathway is activated in clear cell renal cell carcinoma and essential for proliferation of clear cell renal cell carcinoma cells.

Authors:  Sai-Wen Tang; Wen-Hsin Chang; Yih-Ching Su; Yu-Chi Chen; Yen-Han Lai; Pei-Tzu Wu; Chyong-Ing Hsu; Wei-Chou Lin; Ming-Kuen Lai; Jung-Yaw Lin
Journal:  Cancer Lett       Date:  2008-09-21       Impact factor: 8.679

4.  MiR-135a functions as a selective killer of malignant glioma.

Authors:  S Wu; Y Lin; D Xu; J Chen; M Shu; Y Zhou; W Zhu; X Su; Y Zhou; P Qiu; G Yan
Journal:  Oncogene       Date:  2011-12-05       Impact factor: 9.867

5.  miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma.

Authors:  Masayuki Kano; Naohiko Seki; Naoko Kikkawa; Lisa Fujimura; Isamu Hoshino; Yasunori Akutsu; Takeshi Chiyomaru; Hideki Enokida; Masayuki Nakagawa; Hisahiro Matsubara
Journal:  Int J Cancer       Date:  2010-12-15       Impact factor: 7.396

6.  Tumor suppressive microRNA-1 mediated novel apoptosis pathways through direct inhibition of splicing factor serine/arginine-rich 9 (SRSF9/SRp30c) in bladder cancer.

Authors:  Hirofumi Yoshino; Hideki Enokida; Takeshi Chiyomaru; Shuichi Tatarano; Hideo Hidaka; Takeshi Yamasaki; Takenari Gotannda; Tokushi Tachiwada; Nijiro Nohata; Takashi Yamane; Naohiko Seki; Masayuki Nakagawa
Journal:  Biochem Biophys Res Commun       Date:  2011-12-09       Impact factor: 3.575

7.  No improvement in renal cell carcinoma survival: a population-based study in the Netherlands.

Authors:  K K H Aben; T K Luth; M L G Janssen-Heijnen; P F Mulders; L A Kiemeney; D J van Spronsen
Journal:  Eur J Cancer       Date:  2008-05-22       Impact factor: 9.162

8.  Tumor suppressive microRNA‑138 contributes to cell migration and invasion through its targeting of vimentin in renal cell carcinoma.

Authors:  Takeshi Yamasaki; Naohiko Seki; Yasutoshi Yamada; Hirofumi Yoshino; Hideo Hidaka; Takeshi Chiyomaru; Nijiro Nohata; Takashi Kinoshita; Masayuki Nakagawa; Hideki Enokida
Journal:  Int J Oncol       Date:  2012-07-03       Impact factor: 5.650

9.  Tumour suppressive microRNA-874 regulates novel cancer networks in maxillary sinus squamous cell carcinoma.

Authors:  N Nohata; T Hanazawa; N Kikkawa; D Sakurai; L Fujimura; T Chiyomaru; K Kawakami; H Yoshino; H Enokida; M Nakagawa; A Katayama; Y Harabuchi; Y Okamoto; N Seki
Journal:  Br J Cancer       Date:  2011-08-16       Impact factor: 7.640

10.  Comprehensive analysis of clinical significance of stem-cell related factors in renal cell cancer.

Authors:  Yongchao Liu; Changcun Zhang; Jie Fan; Lei Xiao; Bingde Yin; Libin Zhou; Shujie Xia
Journal:  World J Surg Oncol       Date:  2011-10-07       Impact factor: 2.754

View more
  44 in total

1.  MicroRNA-135b regulates ERα, AR and HIF1AN and affects breast and prostate cancer cell growth.

Authors:  Anna Aakula; Suvi-Katri Leivonen; Petteri Hintsanen; Tero Aittokallio; Yvonne Ceder; Anne-Lise Børresen-Dale; Merja Perälä; Päivi Östling; Olli Kallioniemi
Journal:  Mol Oncol       Date:  2015-03-21       Impact factor: 6.603

Review 2.  Oxidative stress response and Nrf2 signaling in aging.

Authors:  Hongqiao Zhang; Kelvin J A Davies; Henry Jay Forman
Journal:  Free Radic Biol Med       Date:  2015-06-09       Impact factor: 7.376

3.  Unveiling the principle of microRNA-mediated redundancy in cellular pathway regulation.

Authors:  Simon Fischer; René Handrick; Armaz Aschrafi; Kerstin Otte
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

4.  MicroRNA-451 regulates chemoresistance in renal cell carcinoma by targeting ATF-2 gene.

Authors:  Xiang Sun; Longhua Lou; Kezhao Zhong; Lijuan Wan
Journal:  Exp Biol Med (Maywood)       Date:  2017-04-21

5.  MicroRNA-based screens for synthetic lethal interactions with c-Myc.

Authors:  Youjun Li; Yahui Zhu; Edward V Prochownik
Journal:  RNA Dis       Date:  2016-05-30

6.  Isolation and structural elucidation of cytotoxic compounds from the root bark of Diospyros quercina (Baill.) endemic to Madagascar.

Authors:  Fatiany Pierre Ruphin; Robijaona Baholy; Randrianarivo Emmanuel; Raharisololalao Amelie; Marie-Therese Martin; Ngbolua Koto-Te-Nyiwa
Journal:  Asian Pac J Trop Biomed       Date:  2014-03

7.  MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia.

Authors:  M Díaz-Beyá; S Brunet; J Nomdedéu; R Tejero; T Díaz; M Pratcorona; M Tormo; J M Ribera; L Escoda; R Duarte; D Gallardo; I Heras; M P Queipo de Llano; J Bargay; M Monzo; J Sierra; A Navarro; J Esteve
Journal:  Leukemia       Date:  2013-09-27       Impact factor: 11.528

8.  Tumor-suppressive miRNA-135a inhibits breast cancer cell proliferation by targeting ELK1 and ELK3 oncogenes.

Authors:  Akhlaq Ahmad; Weijie Zhang; Mingming Wu; Sheng Tan; Tao Zhu
Journal:  Genes Genomics       Date:  2017-10-19       Impact factor: 1.839

9.  Clear cell papillary renal cell carcinoma: micro-RNA expression profiling and comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma.

Authors:  Enrico Munari; Luigi Marchionni; Apurva Chitre; Masamichi Hayashi; Guido Martignoni; Matteo Brunelli; Stefano Gobbo; Pedram Argani; Mohamad Allaf; Mohammad O Hoque; George J Netto
Journal:  Hum Pathol       Date:  2014-01-31       Impact factor: 3.466

Review 10.  Thrombospondin-1 in urological cancer: pathological role, clinical significance, and therapeutic prospects.

Authors:  Yasuyoshi Miyata; Hideki Sakai
Journal:  Int J Mol Sci       Date:  2013-06-07       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.